Joint treatment injections not subject to standardised pricing — JFDA

AMMAN — The Jordan Food and Drug Administration (JFDA) on Thursday said that the joint treatment injection was not subject to standardised pricing until earlier this year, the Jordan News Agency, Petra, reported.

The prices shown in images circulated via social media are outdated, the administration said in a statement carried by Petra.

Joint treatment injections are considered a medical supplies item, according to the JFDA, and such items are internationally not subject to standardised pricing.

However, in an effort to make ensure its affordability, the JFDA said it has already begun enforcing a price range for the injections since the beginning of the year.

The set price ranges from JD40 to JD100, the statement highlighted.

JFDA inspections last year reported multiple price tampering incidents, the administration underlined, hence the price standardisation measure.

As a result, the current average price of the joint injections stands at JD72, “thanks to the JFDA’s price control and monitoring measures”, the statement said.

The administration called on the public to be accurate and subjective when sharing information and to take it from trusted sources, so as not to mislead people.

The statement also said that the JFDA is still carrying out its monitoring role on medicine and take legal actions against violators. 

Meanwhile, MP Khair Abul Saalik, head of the Lower House’s Economy and Investment Committee, said on his twitter account that the injection is sold at JD410 over its baseline cost.

Hyalone injections are taken in the knee joint but are classified as a medical device, which, consequently, makes it out of the jurisdiction of the JFDA, he said. 

Abul Saalik expressed his astonishment that the cost of the injection is JD30 but is sold at JD440, according to the association price tag, as shown in the pictures in question.